Bharat Biotech concludes final analysis for COVAXIN, claims 77.8 pc efficacy from phase-3 clinical trials
Sunday, July 13, 2025
  • Careers
  • Janam TV Malayalam
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms of Services
Janam TV English
  • ‌
  • News
    • Kerala
    • India
    • Gulf
    • World
  • Business
  • Defence
  • Tech
  • Science
  • Health
  • Sports
  • Entertainment
  • ‌
    • Travel
    • Lifestyle
    • Auto
    • Podcast
    • Guest Column
No Result
View All Result
  • ‌
  • News
    • Kerala
    • India
    • Gulf
    • World
  • Business
  • Defence
  • Tech
  • Science
  • Health
  • Sports
  • Entertainment
  • ‌
    • Travel
    • Lifestyle
    • Auto
    • Podcast
    • Guest Column
No Result
View All Result
Janam TV English
No Result
View All Result
  • News
  • Business
  • Defence
  • Health
Home News India

Bharat Biotech concludes final analysis for COVAXIN, claims 77.8 pc efficacy from phase-3 clinical trials

by Janam Web Desk
Jul 3, 2021, 11:34 am IST
in India, Health

Hyderabad, Jul 3 (UNI):   Bharat Biotech, a global leader in vaccine development and innovation, announced on Saturday safety and efficacy analysis data from Phase III clinical trials of COVAXIN®, a whole virion inactivated vaccine against SARS-CoV2, was developed in partnership with ICMR and NIV Pune.

The vaccine maker claimed that the efficacy analysis demonstrates COVAXIN® to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.

It said Efficacy analysis demonstrates COVAXIN® to be 93.4% effective against severe symptomatic COVID-19 and Safety analysis demonstrates adverse events reported were similar to placebo, with 12% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events

The biotechnology company said Efficacy data demonstrates 63.6% protection against asymptomatic COVID-19 and Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant.

Bharat Biotech in a statement said Phase 3 clinical trials of COVAXIN® was an event driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the 2nd dose, conducted at 25 sites across India.

Tags: Phase 3Covaxin clinical trialsCovaxin efficacyMAINFEATUREDBharat BiotechCovaxin
Share15TweetSendShareSendShare

Comments

Refrain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks, name calling or inciting hatred against any community. Keep the conversation civil.

Related News

Kerala

Maoist attack in Wayanad: Police register case under UAPA

Kerala

Members of a pro-CPI(M) organization boycotts election and goes vacationing to protest against policies of left government

India

ABVP submits memorandum to RBI governor demanding strict action against unlawful freezing of Bihar State Universities’ Bank Accounts

Latest News

Weapons spotted in a vehicle used for election campaign of CPI(M)’s Alathur candidate K Radhakrishnan

ABVP writes to NBEMS Chairperson demanding reduction in GPAT-2024 application fee

Congress helped PFI and received their support in return; Communists are vying for PFI support: Says Amit Shah in Alappuzha

Police remove boards welcoming BJP leader K Annamalai to Wayanad

Maoists order locals in a village at Wayanad to boycott the election

Sandeshkhali horror: ABVP sends 6-point memorandum to President Murmu, demands deployment of central forces at Sandeshkhali

Ex-serviceman, whose leg was chopped off by CPI(M), campaigns for Alappuzha NDA candidate Shoba Surendran

Surendran says there is conspiracy behind police action to block image of Lord Ram during Thrissur Pooram

  • Careers
  • Janam TV Malayalam
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms of Services

© Janam Multimedia Limited

No Result
View All Result
  • ‌
  • News
    • Kerala
    • India
    • Gulf
    • World
  • Business
  • Defence
  • Tech
  • Science
  • Health
  • Sports
  • Entertainment
  • ‌
    • Travel
    • Lifestyle
    • Auto
    • Podcast
    • Guest Column

© Janam Multimedia Limited